The QualityStocks Daily Monday, October 21st, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(IMGO) $35.5900 +104.54%

QualityStocks(OZSC) $0.0088 +46.67%

SeriousTraders(SYTA) $0.1942 +26.10%

The QualityStocks Daily Stock List

Ucloudlink Group (UCL)

StreetInsider, StocksEarning, QualityStocks and FreeRealTime reported earlier on Ucloudlink Group (UCL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ucloudlink Group Inc. (NASDAQ: UCL) is a mobile data traffic sharing marketplace engaged in the provision of wireless telecommunication services.

The firm has its headquarters in Kowloon, Hong Kong and was incorporated in 2014, on August 25th by Zhi Ping Peng and Chao Hui Chen. It operates in the communications sector, under the telecommunications industry. The firm has seven companies in its corporate family and serves consumers around the globe.

The company is focused on providing premium user experience by offering a reliable, safe and dynamic network based on its patented and universal Cloud SIM technology. Its services and products offer unique value propositions to mobile network operators, mobile virtual network operators, smart-hardware companies and mobile data users.

The enterprise’s products include a model focused on cross-border travelers who need mobile data connectivity services in different jurisdictions, known as uCloudlink 1.0; and a model that offers mobile data connectivity services to local users via different mobile network operators, known as uCloudlink 2.0. It also provides a world phone series dubbed GlocalMe; uCloudlink 3.0, which includes B2B2C wholesale, B2C retail and software-as-a-service/platform-as-a-service platform-based connectivity ecosystem. The enterprise offers integrated network solutions to its customers; value added services; and SIM cards with prepaid data packages.

The company recently announced its latest financial results for 2021 which show increases in its total revenues. Its CEO noted that the increase observed was an indication that the company was well-positioned to grow due to its efforts to expand its platform-centric business. Currently, the company is focused on expanding its network and strengthening its collaborations with local partners.

Ucloudlink Group (UCL), closed Monday's trading session at $3.47, up 30.9434%, on 2,998,248 volume. The average volume for the last 3 months is 5.251M and the stock's 52-week low/high is $0.46/$6.9699.

NeuroOne Medical Technologies (NMTC)

QualityStocks, PCG Advisory, StockStreetWire, Small Cap Firm, Wolf of Penny Stocks, TopPennyStockMovers, MarketBeat, Make Penny Stocks Great Again, Fierce Analyst and Epic Stock Picks reported earlier on NeuroOne Medical Technologies (NMTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology firm that is engaged in developing and commercializing film electrode technology for sEEG and cEEG recording, ablation, brain stimulation and spinal cord stimulation solutions for patients with neurological disorders.

The firm has its headquarters in Eden Prairie, Minnesota and was incorporated in 2009, on August 20th. Prior to its name change, the firm was known as Original Source Entertainment Inc. It serves consumers in the U.S.

The company values methodical research, quality work and is party to various lasting collaborations with leading experts in its field. It has an experienced management team and has assembled impressive AI and scientific advisory boards.

The enterprise is committed to offering high-definition and minimally invasive solutions for patients with various disorders. Its thin film electrode technology allows for higher density contacts, which increases signal acquisition and mapping resolution. The enterprise’s technology is made up of three main types of cortical electrodes namely, dual-sided electrodes, strip electrodes and grid electrodes. The technology is used for sEEG (stereoelectroencephalography) and cEEG (electroencephalogram) recordings for patients suffering from dystonia, essential tremors, Parkinson’s disease, epilepsy and chronic pain caused by failed surgeries. The technology decreases procedural costs and improves patient outcomes.

The firm recently entered into a strategic partnership agreement with RBC Medical Innovations, which entails the development and manufacture of a radiofrequency generator. This move will allow the firm to fully participate in the growing market, which may encourage more investments into the firm and boost the firm’s growth.

NeuroOne Medical Technologies (NMTC), closed Monday's trading session at $1.2, up 42.8571%, on 5,250,948 volume. The average volume for the last 3 months is 66.256M and the stock's 52-week low/high is $0.5101/$3.18.

Meta Materials (MMAT)

Schaeffer's, InvestorPlace, QualityStocks, MarketClub Analysis and MarketBeat reported earlier on Meta Materials (MMAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Meta Materials Inc. (NASDAQ: MMAT) is a smart materials and photonics firm that is engaged in the invention, design, development and manufacture of different functional materials and nanocomposites.

The firm has its headquarters in Dartmouth, Canada and was incorporated in 2021, on June 23rd by Themos Kallos and George Palikaras. It operates as part of the materials sector, under the chemicals sub-industry and serves consumers across the globe.

The enterprise specializes in the manufacture of highly functional films that have been engineered at the nanoscale to harness electromagnetic waves and the power of light. Its technology platform comprises of 3 core capabilities, namely wireless sensing, lithography and holography. This allows the enterprise to develop a library of functional prototypes and solutions at lower costs and at a much faster pace than traditional chemical synthesis. The enterprise serves the 5G communications, health and wellness, consumer electronics, clean energy, aerospace and defense and automotive industries across the globe and has sales as well as research and development offices in the Silicon Valley and London.

The company’s sustainable higher performance multi-use products employ the use of lightweight raw materials and processes to provide superior performance and consume less energy. Its products include a holographic optical component known as holoOPTIX; a revolutionary transparent conductive film dubbed NANOWEB; and a laser glare protection eyewear known as metaAIR. In addition to this, the company also develops Glucowise.

The firm recently concluded a project to develop a non-invasive glucose sensing prototype which can accurately predict changes in glucose level in diabetes patient. The prototype eliminates the need to draw blood in order to measure glucose levels. Its success will not only benefit patients with diabetes but also extend the firm’s consumer reach, which will be good for investments.

Meta Materials (MMAT), closed Monday's trading session at $2.16, up 30.1205%, on 67,466,517 volume. The average volume for the last 3 months is 67.267M and the stock's 52-week low/high is $0.63/$4.27.

OZOP Energy Solutions (OZSC)

QualityStocks and InvestorPlace reported earlier on OZOP Energy Solutions (OZSC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OZOP Energy Solutions Inc. (OTC: OZSC) is focused on the design, manufacture and distribution of power electronics and endoscopic instruments.

The firm invents and develops power supplies, converters, inverters and ultra-high power chargers for various applications in the maritime, aircraft ground support, heavy industrial and defense sectors. OZOP Energy Solutions Inc. serves consumers across the globe.

The firm, which was known as OZOP Surgical Corp before changing its name, has its headquarters in Warwick, New York. OZOP Energy Solutions Inc. was established on July 17, 2015 and operates through the Hong Kong and United States geographical segments.

OZOP Energy Solutions also provides surgical devices, instrumentation and implants, which focus on neurological, spine and pain management specialties and procedures. The firm’s AC (alternating current) and DC (direct current) power supplies, which are available in ratings from 5KW (kilowatt) to 20 MW (megawatt), are utilized in multi-pulse silicon control rectifier, insulated gated bipolar transistor design. They provide low output noise, precise regulation, low ripple and also help achieve efficiency. The firm also offers a frequency converter for any military, industrial or commercial application with power ranges from 4KVA to 500 KVA (kilovolt-ampere). This is in addition to providing 400 hertz aircraft ground support equipment and manufacturing all types of power inverters, including electrostatic precipitators, power transmissions, solar cell power stations, AC/AC inverters, DC/AC inverters and DC/DC inverters.

OZOP Energy Solutions Inc. recently announced that they’d be developing the first contract energy systems for non-grid solutions. This move aligns with the firm’s expansion plan and with energy use in the U.S. set to increase significantly, the energy production industry is bound to need help in meeting the population’s needs, which is where the firm is set to gain hefty returns for its shareholders.

OZOP Energy Solutions (OZSC), closed Monday's trading session at $0.0088, up 46.6667%, on 67,267,158 volume. The average volume for the last 3 months is 382,572 and the stock's 52-week low/high is $0.00555/$0.059.

Atea Pharmaceuticals (AVIR)

MarketClub Analysis, StreetInsider, Marketbeat.com, MarketBeat, InvestorPlace, The Online Investor and Schaeffer's reported earlier on Atea Pharmaceuticals (AVIR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Atea Pharmaceuticals Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical firm is engaged in the discovery, development and commercialization of anti-viral therapies for patients who suffer from viral infections.

The firm has its headquarters in Boston, Massachusetts and was incorporated in July 2012 by David Chu and Jean-Pierre Sommadossi. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. It is party to a license agreement with Merck & Co. Inc., which entails developing and commercializing Ruzasvir for treating HCV.

The enterprise’s product pipeline is comprised of an antiviral drug candidate dubbed AT-527, which is in phase 2 trials evaluating its effectiveness in treating the coronavirus; an oral purine nucleoside pro-drug product candidate dubbed AT-752, which has concluded phase 2a trials for dengue treatment; and an investigational oral, pan genotypic NS5A inhibitor dubbed Ruzasvir, for the treatment of chronic HCV infection. It also develops a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, known as AT-281.

The company, which recently announced its latest financial results, remains committed to conducting clinical trials for its formulations as well as advancing its clinical programs and pipeline. This will not only bring the company closer to getting its candidates approved but also help bring in additional revenues and investments.

Atea Pharmaceuticals (AVIR), closed Monday's trading session at $4.52, off by 3.212%, on 386,751 volume. The average volume for the last 3 months is 381,124 and the stock's 52-week low/high is $4.45/$9.79.

Standard BioTools (LAB)

OTCPicks reported earlier on Standard BioTools (LAB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Standard BioTools Inc. (NASDAQ: LAB) (FRA: FLB) is a company focused on the creation, manufacture and marketing of instruments, consumables, software and reagents for clinical labs and scientists.

The firm has its headquarters in South San Francisco, California and was incorporated in 1999, on May 1999 by Gajus Vincent Worthington and Stephen D. Quake. Prior to its name change in April 2022, the firm was known as Fluidigm Corp. It operates as part of the diagnostics and research industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to license agreements with Caliper Life Sciences Inc., Harvard University and California Institute of Technology. It generates the majority of its revenues from the United States followed by EMEA and Asia-Pacific.

The enterprise provides analytical systems such as a CyTOF system dubbed Helios, as well as Hyperion tissue imagers, Hyperion imaging systems and flow conductors; assays and reagents, including Maxpar direct immune profiling assays, Maxpar reagents and IMC panel kits for immuno-oncology use. It also provides integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC and Flex Six IFC; and assays and reagents, including Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, Advanta RNA-Seq NGS library prep kits, access array target-specific primers and targeted DNA Seq library assays.

The firm recently entered into a partnership agreement with Visiopharm, which will involve the companies imaging systems and analysis software. This is in addition to extending the firm’s consumer reach and opening it up to new growth and investment opportunities.

Standard BioTools (LAB), closed Monday's trading session at $1.35, off by 5.5944%, on 381,124 volume. The average volume for the last 3 months is 35,652 and the stock's 52-week low/high is $0.92/$4.85.

X Financial (XYF)

TradersPro, MarketBeat, Trading Concepts, StreetInsider and BUYINS.NET reported earlier on X Financial (XYF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

X Financial (NYSE: XYF) is a technology-driven personal finance firm that is engaged in the provision of the personal financial services.

The firm has its headquarters in Shenzhen, China and was incorporated in 2015, on January 5th by Yue Tang. It operates as part of the credit services industry, under the financial services sector. The firm serves consumers in the People’s Republic of China.

The company is committed to connecting borrowers on its platform with its institutional funding partners. Through its proprietary big data-driven technology, it has established strategic partnerships with financial institutions across multiple areas of its business operations, enabling it to facilitate loans to prime borrowers under a robust risk assessment and control system. The company generates revenue from loan facilitation service, post-origination service, and guaranteeing services provided.

The enterprise provides services as an online marketplace connecting borrowers and investors. Its loan products include Xiaoying credit loan, which comprises of Xiaoying preferred loan to small business owners; Xiaoying card loan; and Xiaoying revolving loan. It also provides a home equity loan product for property owners known as Xiaoying housing loan; investment products through Xiaoying wealth management platform, such as money market, loans and insurance products; and loan facilitation services to other platforms.

The firm recently announced its latest financial results, with its CEO noting that their performance demonstrated its proven strategy, effective strategic positioning and strong execution capability. It remains focused on delivering sustainable growth in the long-term, which will benefit its shareholders.

X Financial (XYF), closed Monday's trading session at $2.01, off by 12.987%, on 35,721 volume. The average volume for the last 3 months is 54,629 and the stock's 52-week low/high is $1.62/$4.8381.

Genetron Holdings (GTH)

StreetInsider, StocksEarning, MarketBeat and BUYINS.NET reported earlier on Genetron Holdings (GTH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genetron Holdings Ltd (NASDAQ: GTH) is a precision oncology firm that is focused on cancer molecular profiling and harnessing technologies in data sciences and molecular biology for cancer treatment.

The firm has its headquarters in Bejing, the People’s Republic of China and was incorporated in 2015 by Wei Wu He, Hai Yan and Si Zhen Wang. It operates as part of the diagnostics and research industry, under the healthcare sector. The firm serves consumers around the globe.

The company is focused on transforming cancer treatment. It has developed a comprehensive product and service portfolio that covers the full-cycle of cancer care. The company is party to a strategic partnership with JD Health, involving the creation of solutions for full-cycle cancer management.

The enterprise provides diagnosis and monitoring services, and early screening services through laboratory developed test services. It also offers in-vitro diagnostic products, including a semiconductor-based NGS system dubbed Genetron S5, which detects nucleotides through detecting the change in pH; an IVD assay product to detect lung cancer known as 8-gene lung cancer assay; Genetron 3D biochip reading instrument; a genomic profiling service for various solid tumors dubbed Onco PanScan; Genetron Chef System; and a production-scale sequencer known as the Genetron S2000 platform.

The company, which recently launched the Genetron Health Cancer Early Screening Center and the Genetron Health Future Science and Technology Experience Hall, is committed to supporting the development of national projects for early screening for comprehensive prevention and control of liver cancer. This will positively influence the company’s growth as well as generate significant shareholder value.

Genetron Holdings (GTH), closed Monday's trading session at $0.963, off by 2.7076%, on 54,629 volume. The average volume for the last 3 months is 401,541 and the stock's 52-week low/high is $0.7311/$12.01.

Milestone Pharmaceuticals (MIST)

MarketBeat, MarketClub Analysis, StreetInsider, Trades Of The Day, StockMarketWatch, QualityStocks, Daily Trade Alert, BUYINS.NET, Schaeffer's and InvestorsUnderground reported earlier on Milestone Pharmaceuticals (MIST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a biopharmaceutical firm that is engaged in developing and commercializing cardiovascular drugs.

The firm has its headquarters in Montreal, Canada and was incorporated in 2003 by Philippe Lamarre and Philippe Douville. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in Canada.

The patient-centric company has assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors. It is party to a license and collaboration agreement with Ji Xing Pharmaceuticals, which entails developing and commercializing etripamil for prophylactic and therapeutic uses in humans. The company employs a lean and cost-efficient model which has the effect of minimizing overhead and focusing spending on the programs.

The enterprise’s product pipeline is comprised of etripamil, a novel, potent and short-acting calcium channel blocker that has been designed as a rapid-onset nasal spray, which is self-administered by patients. The novel channel blocker is in phase 2 trials for the treatment of rapid ventricular rate and atrial fibrillation; and phase 3 trials evaluating its effectiveness in treating paroxysmal supraventricular tachycardia (PSVT) in Canada and the United States.

The firm recently released its latest financial results, with its CEO noting that they remained focused on submitting the etripamil formulation New Drug Application to the FDA. The success and approval of this formulation will benefit patients with this indication, while also bolstering the firm’s growth.

Milestone Pharmaceuticals (MIST), closed Monday's trading session at $4.74, up 3.7199%, on 401,541 volume. The average volume for the last 3 months is 22.242M and the stock's 52-week low/high is $3.9801/$9.8465.

Coinbase Global Inc. (COIN)

InvestorPlace, Prfmonline, Schaeffer's, The Street, Greenbackers, MarketClub Analysis, Kiplinger Today, MarketBeat, OTCPicks, SmallCapVoice, QualityStocks, Ceocast News, HotOTC, CoolPennyStocks, Daily Trade Alert, StockEgg, Trades Of The Day, Penny Invest, Stock Stars, The Online Investor, Stock Rich, StocksEarning, The Wealth Report, Investopedia, Top Gun, Top Pros' Top Picks, BestOtc, The Stock Psycho, HotShotStocks, StockHotTips, CNBC Breaking News, BullRally, PennyStockVille, MadPennyStocks, FeedBlitz, PennyTrader Publisher, Stockpalooza, StockRich, Today's Financial News, Wealth Daily, PennyInvest, Profit Confidential, WiseAlerts, Stock Traders Chat, BloomMoney, Eagle Financial Publications, Blaque Capital Stocks, wyatt research newsletter, CRWEWallStreet, Atomic Trades, Dynamic Wealth Report, Pennybuster, Green Chip Stocks, Penny Stock Finder, Stock Fortune Teller, Stock Analyzer, Standout Stocks, Round Up the Bulls, Louis Navellier, Zacks, MicrocapVoice, Momentum Traders, AllPennyStocks, Penny Stock Rumble and StockMister reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

At the simplest level, fractional investing allows investors to buy and own a fraction of a company’s share. When you buy shares on stock exchanges, you are buying a small part of a company whose shares are listed. With fractional investing, you get ownership of less than one share of that company. New technologies such as blockchain technology are widening the possibilities presented by fractional investing.

For example, the Singapore-based ADDX platform makes it possible for investors to buy a stake in a diverse range of assets for as little as $5,000 as the minimum one can have to join the platform. Previously, one needed at least a million dollars to participate in investing in that portfolio of assets. Smart contracts and blockchains have made this level of fractional investing possible.

To illustrate this further, think about how much one would need to create an investment portfolio of vintage wines. Each vintage wine is worth thousands of dollars or even tens of thousands of dollars, so it would be extremely expensive to create a diversified portfolio of vintage wines in order to avoid the risk that comes from focusing on just one wine maker. Needless to say, only the ultra-rich have been able to invest in vintage wines since they are the only ones who could afford the high upfront costs associated with putting together such a portfolio.

However, fractional investing that leverages blockchain technology can reduce the investment costs by a huge fraction because one would only need to acquire a tiny stake in each vintage wine in a portfolio.

Blockchain-enabled fractional investing also allows investors to structure and restructure their investment portfolios as needed. For example, if one wants 10% of their portfolio to be held in real estate, fractional investing allows the person to liquidate sections of their holdings so that what is left is exactly what is needed to keep the holding at 10% of the portfolio at a time when the shares are appreciating rapidly. The same approach can be used to increase holdings to a precise fraction of the entire portfolio.

The above flexibility also brings benefits in terms of risk management. Blockchain technology is now making it possible for retail investors to access various assets based on how much risk they are willing to take. For example, a first-time investor might be nervous about using $100,000 to buy a stake in one company. However, putting up $300 through fractional investing is easier for such a novice to stomach, especially if that money is going to a diversified pool of entities within the same industry.

Other entities, such as Coinbase Global Inc. (NASDAQ: COIN), demonstrate the different ways through which blockchain and other new technologies can have real-world relevance for ordinary people.

Coinbase Global Inc. (COIN), closed Monday's trading session at $41.23, off by 8.9041%, on 22,381,981 volume. The average volume for the last 3 months is 191,348 and the stock's 52-week low/high is $40.61/$335.90.

Compass Pathways PLC (CMPS)

InvestorPlace, QualityStocks, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics have taken the world by storm in recent years, with investors pouring millions of dollars into psychedelic research and more people considering them as alternative treatments. Research has shown that going through a “psychedelic experience” under controlled and safe conditions can result in profound mental health benefits.

Long before researchers started studying hallucinogenic drugs, people across the world used the substances recreationally because of their unique psychoactive effects. Recent research has now revealed that psychedelic drug use may have started much earlier than anyone thought.

A recent study by Dagmara Socha, a PhD student at the University of Warsaw’s Center for Andean Studies, has found that ancient Peruvians may have consumed psychedelic drugs in their religious and cultural rituals. Researchers studied a set of 22 mummified human remains from Peru and found compelling evidence that ancient civilizations situated along Peru’s southern coast used psychedelics and even engaged in long-distance trade to acquire said psychedelics.

According to the researchers, their findings point to what could be the earliest-known use of ayahuasca’s main ingredient, bantisteriopsis, and the San Pedro cactus that produced mescaline. The findings will be published in the December edition of the “Journal of Archaeological Science.”

The set of mummified human remains included four trophy heads, which are likely a result of the Nazca culture of headhunting. These heads consisted of a female adult, two adult males, and a child whose gender was inconclusive. Researchers found traces of psychedelics on the child and female’s heads, a sign that they may have been given hallucinogenic stimulants before they died. Traces of mescaline were found in the child’s hair, an indication that they ingested the San Pedro cactus, which has long been used for its hallucinogenic effects.

Furthermore, there were traces of benzoylecgonine in the female’s hair, researchers say, which is a major metabolite of cocaine. The researchers posited that the presence of this metabolite indicates that the female chewed on coca leaves before her death.

Since most of the trophy heads come from the Early Nazca period stretching from 0–450 CE, the researchers believe that the two males, the female, and the child met their end through ritual sacrifice. Their findings are proof that some ancient individuals consumed psychedelic drugs before they were sacrificed.

Furthermore, the researchers add that the presence of psychedelic plants in civilizations along the southern Peruvian coast indicates that there may have been established long-distance trade routes as the plants were not local to those civilizations.

The findings of this archeological study make a good case for the relative safety of the psychedelic substances that companies such as Compass Pathways PLC (NASDAQ: CMPS) are seeking to develop medicinal formulations from, given such a long history of use around the world.

Compass Pathways PLC (CMPS), closed Monday's trading session at $9.58, off by 3.8153%, on 191,348 volume. The average volume for the last 3 months is 7.529M and the stock's 52-week low/high is $6.54/$34.79.

QuantumScape Corp. (QS)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, The Street, The Online Investor, MarketBeat, Daily Trade Alert, Top Pros' Top Picks, QualityStocks, TipRanks, wyatt research newsletter, Atomic Trades, Trades Of The Day, CNBC Breaking News and BUYINS.NET reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

One of the states where residents advocate for climate change through municipal officials is California — a state that is known for backing climate-related tax legislation. In June, a tax on California’s super-rich was proposed in order to raise money for electric vehicles and bush fire prevention, but the ballot measure was defeated by 59% of voters casting ballots against it, leaving many to wonder how such a widely supported initiative could lose in a state that highly advocates for climate change.

At a glance, the initiative appeared to be winning due to the overwhelming support received from the American Lung Association, the Union of Concerned Scientists and other public groups. However, things became chaotic toward in July, right when the California Democratic Party backed Proposition 30. A group of billionaires and the California Teachers Association, as well as Governor Gavin Newsom, who betrayed his party, launched an opposition movement against it.

The Union of Teachers objected to the placing of interest on income tax, which is typically used to pay for schools. On the other hand, Governor Newsom focused his attention on LYFT, the main financier of the proposition. The governor has been actively opposing the measure since September, urging the residents of California to reject Lyft’s devious ploy to seize the taxpayer-funded subsidy. The governor went so far as to use campaign funds meant for his re-election to oppose the measure.

According to Catherin Wolfram, Newsom has a significant voice as a climate activist in the state, which is why voters heeded his call when he went against Proposition 30. According to California law, rideshare enterprises must record 90% of the kilometers driven in electric vehicles by 2030. Newsom charged Lyft with attempting to utilize tax money in its bid to switch to electric vehicles. As soon as Newsom voiced his opposition to the proposal, its popularity began to decline.

According to the organizations that developed the measure, Lyft joined the initiative primarily to fund it, despite the claims raised by the governor.

In addition to distrust regarding Lyft’s involvement, other opponents supported the fight Proposition 30. Those with annual incomes of more than $2 million, for example, would bear the brunt of the 1.75% tax increase. These billionaires were among the top contributors to the campaign against Proposition 30, and their financial muscle ensured that voices opposed to the measure were heard across the state, with the devastating effect of the measure being rejected at the polls.

While the voter measure in California failed, that doesn’t mean that the forward march of the electric vehicle industry and its numerous actors, including QuantumScape Corp. (NYSE: QS), have been dealt a fatal blow. Demand is growing rapidly, and is unlikely to slow down in the decades to come.

QuantumScape Corp. (QS), closed Monday's trading session at $6.86, off by 4.9861%, on 7,564,975 volume. The average volume for the last 3 months is 218,027 and the stock's 52-week low/high is $6.73/$36.74.

The QualityStocks Company Corner

Vision Energy Corp. (OTCQB: VIHDD)

The QualityStocks Daily Newsletter would like to spotlight Vision Energy Corp. (OTCQB: VIHDD).

Vision Energy is in advanced stages of planning for constructionand delivery of Northwestern Europe’s first import, storage andhandling terminal designed exclusively for hydrogen carriers,renewable energy products and low-carbon fuels

Vision Energy, through its wholly owned subsidiary EvolutionTerminals BV, just announced partnership with Linde Engineering, aleading global industrial gases and engineering company, to deliverpreliminary Front-End Engineering and Design (“FEED”) services tothe project

Green Energy Terminal Project will accelerate and advance theenergy transition and facilitate Northwestern Europe’s ambition toachieve Net Zero through carbon-abatement and adoption of hydrogenas a core feedstock and fuel

Committed to providing the lowest carbon solutions with the highestyield hydrogen production, Vision Energy (OTCQB: VIHDD) just announced another milestone in the development of thecompany’s pioneering Green Energy Terminal in North Sea Port ofVlissingen, the Netherlands. In a recent press release Vision Energy reported it has entered into a cooperation agreementwith Linde Engineering to accelerate engineering efforts for thecompany’s pioneering Green Energy Terminal in North Sea Port ofVlissingen, the Netherlands. Linde Engineering, a leading globalindustrial gases and engineering company with 2021 sales of $31billion, will deliver preliminary Front-End Engineering and Design(“FEED”) services to the project including design and engineeringof 150,000 cubic meters (“CBM”) of Green Ammonia (“NH3”) storage,truck and barge loading facilities, ship loading and unloadingfacilities, as well as utilities, infrastructure and buildings.

Vision Energy Corp. (OTCQB: VIHDD) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains.

The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs.

According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region.

Vision Energy is based in Jersey City, New Jersey.

Projects

Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products.

Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (CBM) of storage capacity with land already secured for future expansion.

Market Opportunity

In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years.

The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source.

The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal.

Vision Energy projects its total addressable market at €10 billion by 2050.

Management Team

Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia.

Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products.

Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated, managing over $30 million in annual revenue. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers.

Vision Energy Corp. (OTCQB: VIHDD), closed Monday's trading session at $11.24, up 17.6963%, on 218,027 volume. The average volume for the last 3 months is 527,360 and the stock's 52-week low/high is $1.25/$19.01.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”)Innovation Summit and Shark Tank Competition

Company’s presentation included an overview of its HeartBeam AIMI™platform, which aids in more precise heart attack diagnosis

HeartBeam is building an intellectual-property portfolio focused onenabling 12-lead electrocardiogram (“ECG”) diagnostics outside of amedical setting

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first andonly 3D-vector ECG platform for heart attack detection anytime,anywhere, has been named winner of the annual CardiovascularInnovations (“CVI”) 2022 Innovation Summit and Shark TankCompetition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions forcardiology clinicians who participate in the care of patients withcoronary, peripheral and structural cardiovascular diseases; awardspresented at the conference recognize state-of-the-art cardiactechnologies.

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Monday's trading session at $4.04, up 27.4448%, on 527,360 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $19.01/$.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

In November 2021, Lexaria laid out its plans for several new andongoing R&D programs, among them hormone replacement, dementia,rheumatoid disease, and diabetes

The company has since begun its DIAB-A22-1 study program on theeffectiveness of the patented DehydraTECH(TM)-processed CBD for thepotential therapeutic utility against diabetes

Lexaria is optimistic that the study will yield some notableresults, particularly with DehydraTECH-CBD having met primarysafety and efficacy objectives from its HYPER-H21-4 clinical studyon the potential treatment of hypertension

So far, CBD has shown some ability to reduce the incidence ofdiabetes in mice, and Lexaria looks to build on these findings and investigate DehydraTECH’s overall effectiveness for the potentialtreatment of the disease among human patients

DIAB-A22-1 marks a notable milestone for Lexaria and is a testamentto the company’s commitment to advancing its efforts to addressunmet patient needs and create shareholder value

In November 2021, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency oforally-delivered fat-soluble active molecules and drugs, announcedits plans for several new and ongoing research and development(“R&D”) programs on its patented DehydraTECH(TM) technology forthe 2022 calendar year. The study areas included hormonereplacement, dementia, rheumatoid disease, and diabetes (https://cnw.fm/SDZ4W).Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in aninterview produced by PCG Digital Holdings LLC and published on NewMediaWire. John Docherty, Lexaria’s president and head of research,discussed the company’s efforts to investigate the potentialtherapeutic utility of its proprietary DehydraTECH(TM)-CBD againstdementia and diabetes, two of the world’s largest public healthcrises. Lexaria recently demonstrated DehydraTECH-CBD’s exceptionalsafety and tolerability in a human hypertension study, as well asstatistically significant lowering of blood pressure over multipleweeks (something that previous studies by others have failed toevidence). Strong connections exist between hypertension, dementiaand diabetes. “Hypertension and dementia are linked. Clinicalstudies have shown that individuals who have high blood pressureare more likely to develop vascular dementia. Similarly, there arestrong connections between heart disease, hypertension anddiabetes. Hypertension is twice as frequent in diabetics, andhypertensive patients are at greater risk of developing diabetes,”Docherty said. “We are excited to investigate whetherDehydraTECH-CBD has a potential application in the treatment ofdementia and diabetes based on its propensity to cross theblood-brain barrier, the fact that DehydraTECH-CBD lowers humanblood pressure and the fact that CBD is known to have vasodilatory,anti-inflammatory and antioxidant effects.” To view the full pressrelease, visit https://ibn.fm/WohVf

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $2.22, up 0.909091%, on 3,674 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$6.11.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, todayannounced that its CEO Amir Reichman will present at the upcomingBiotech Showcase conference. The event is slated to take place Jan.9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”)41st Annual Health Care Conference. Reichman will be available tomeet potential partners, collaborators and investors. Interestedparties should visit https://ibn.fm/p6eOA or https://ibn.fm/tcHsS or contact BiondVax Investor Relations at +972-8-930-2529 or ir@biondvax.com to request a one-on-one appointment. To view the full pressrelease, visit https://ibn.fm/BNkPf. When state residents start growing their own marijuana legally,market opportunities could open up for companies that makeequipment to facilitate cannabis cultivation indoors, such as Advanced Container Technologies Inc. (OTC: ACTX).

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Monday's trading session at $0.8776, up 0.873563%, on 10,097 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.5335/$3.49.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Americans in five states have had the chance to vote on cannabis legalization during theMidterm elections. In Missouri, voters approved a cannabis legalization initiative dubbed Amendment 3, which wouldallow adults age 21 and older to purchase and possess up to threeounces of marijuana. Adults would also be able to grow up to siximmature plants, six clones and six flowering plants at home oncethey secure a registration card. The initiative was pushed by Legal Missouri 2022, a campaign that worked for months to convince Missourians to votein favor of the measure. Missouri lawmakers have acted quickly inthe wake of the legislation’s passage. Only two days afterMissourians approved Amendment 3 at the ballot, the MissouriDepartment of Human and Health Services (DHHS) unveiled draftcannabis legislation for the state’s recreational cannabis marketand launched a public comment period. When state residents startgrowing their own marijuana legally, market opportunities couldopen up for companies that make equipment to facilitate cannabiscultivation indoors, such as Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Monday's trading session at $0.3895, up 44.0459%, on 412 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”), a technologycompany developing solutions to optimize and automate the supplychain process and providing its Fr8App platform for B2Bcross-border shipping in the NAFTA region, today reports thirdquarter 2022 revenue for the period ended Sept. 30, 2022. Fr8Techreported strong quarterly revenue of $7.7 million for Q3 2022,which is an increase of 38% from $5.6 million in Q3 2021, and thecompany reported $21.5 million in YTD Q3 revenue, which is anincrease of 32% from $16.3 million for YTD Q3 2021. Managementadjusted full-year 2022 revenue guidance to $29-30 million, upnearly 35-40% from Fr8App’s 2021 full-year revenue of $21.5million.

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Monday's trading session at $0.355, up 15.9373%, on 9,634,494 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1799/$8.734.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Brain cancer affects an estimated 30 out of every 100,000 Americans. The debilitating disease currently has no cure but can often bemanaged by treatments such as radiation therapy, chemotherapy andsurgery. However, these treatments aren’t always as effective asthey could be due to one major obstacle: the blood-brain barrier.This is a system of specialized brain microvascular endothelialcells (BMVEC) that provides brain tissues with nutrients, filtersout harmful substances from the brain to one’s bloodstream, andprevents toxic substances from entering the brain. While theblood-brain barrier undoubtedly serves a critical role, it oftenmakes cancer treatments less effective by preventing medicine inthe blood from reaching brain tumors. As more treatment optionscome from for-profit entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) and knowledge about how to bypass the roadblocks that have madebrain cancers hard to treat, patients may have better prospects ofsurviving and even thriving after a cancer diagnosis.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.207, up 3.5%, on 145,665 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.16/$1.38.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

• RNG is considered carbon-neutral because it is derived from organicsources that produce methane emissions while decaying

• EverGen is developing Canadian RNG infrastructure with projects inBritish Columbia, Alberta, and Ontario

• EverGen’s expansion projects backed by Canada’s highly regulatedenergy sector, supported with long-term contracted revenueagreements

According to the United Nations, the future of clean energy dependson fuel sources that are economical and reliable while minimizingcarbon emissions (https://ibn.fm/NSl40). Sources with a minimal or zero carbon footprint like liquifiednatural gas (“LNG”), solar panels, and wind turbines are viableoptions, however renewable natural gas (“RNG”) provides a strongerimpact by removing carbon from the atmosphere.EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) is dedicated to a net-zero future that leverages renewable energysources like RNG. The company leads RNG adoption efforts acrossCanada by acquiring, developing, building, and operating aportfolio of RNG and related waste-to-energy projects whiledeveloping a domestic RNG platform.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Monday's trading session at $1.6401, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$4.21.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Dozens of countries worldwide have pledged to transition away from dirty fuels such as coal and oil as part of global efforts to arrest climatechange and global warming. Although solar, wind and geothermalenergy are already poised to play a significant role in the greenenergy transition, nuclear energy hasn’t received as much attention.Over the past couple of decades, many countries that have nuclearpower plants have steadily shut down their nuclear reactors amid increasing fears of nuclear accidents and their fallout.However, recent geopolitical events have forced these countries togo back to the drawing board and pause their nuclear shut-downplans. In the meantime, players such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are likely to maximize production at their current mine sites asthey study the long-term outlook of nuclear energy beforecommitting resources to developing new mining operations.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday's trading session at $6.74, off by 3.9886%, on 2,019,245 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.69/$11.00.

Recent News

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Arizona Metals owns 100% of two copper and gold explorationprojects in mining-friendly Arizona

Both projects have excellent infrastructure, including roads,available power and water access

Only 3% of the prospectively mineralized trend that hosts thehigh-grade Kay Mine Deposit has been drilled

The company had $60 million in cash as of June 30, 2022, tocomplete Phase 2 and begin Phase 3 drilling at the Kay Mine

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Vision Energy Corp. (OTCQX: AZMCF), closed Monday's trading session at $2.86, off by 0.866551%, on 42,554 volume. The average volume for the last 3 months is 42,554 and the stock's 52-week low/high is $2.30/$5.60.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton signed binding agreement with established automotivelighting tier 1 supplier Koito for investment of $100 million tobolster its next stage of growth

Agreement penned on October 27, 2022, marks the third investmentfrom this long-term automotive Tier 1 partner and existingshareholder since 2020

Lidar market expected to grow rapidly to reach $59 billion by 2030;Cepton appears to continue leading as a prominent figure, as itworks toward commercialization and mass market deployment of itslidar sensors

Following a previously reported letter of intent from KoitoManufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered into a binding investmentagreement for a $100 million investment from its long-termautomotive Tier 1 partner and current shareholder (https://ibn.fm/LjTSk). This Silicon Valley innovator and leader in high-performancelidar solutions intends to use this investment — Koito's thirdsince 2020 — to fund the company's next growth stage as it looks toexecute its vision to scale lidar technology for mass deployment.Under the terms of the Investment Agreement, unanimously approvedby Cepton's board of directors, Koito will purchase $100 million ofconvertible preferred stock. This stock will be convertible,beginning on the first anniversary of the issue date, into sharesof Cepton’s common stock at an approximate initial conversion priceof $2.23 per share, representing a 10.0% premium to Cepton’svolume-weighted average price over the trailing 20 trading dayperiod. As well as a 13.4% premium 14.4% 30-day VWAP and a 25.5%90-day VWAP. The company expects to close the investment in thefirst quarter of 2023, subject to the approval of Cepton'sshareholders and satisfaction of relevant closing conditions. Moreinformation regarding the key terms of the investment is includedin a Form 8-K that Cepton recently filed with the US Securities andExchange Commission (https://ibn.fm/tnrlO).

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $1.36, off by 3.5461%, on 176,448 volume. The average volume for the last 3 months is 174,908 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Worldwide initiatives to slash carbon emissions, recently bolsteredby the Inflation Reduction Act in the United States, areunderpinned by EV uptake, which needs innovation to scale and reachcritical mass

Hillcrest Energy Technologies has developed a cutting-edge250-kilowatt, 800-volt Silicon Carbide (“SiC”) EV inverter that hascaptured the attention of leading firms

Hillcrest has recently inked new partnerships, including one with aglobal Tier 1 automotive supplier, for the purpose ofcommercializing new inverters for electric mobility applications

With 1.4 billion vehicles in use today and around 1 percent of thempowered by electricity, the move to decarbonize the transportationindustry is accelerating yet also has far to go. The U.S. InflationReduction Act signed into law in August is arguably the mostsignificant piece of U.S. legislation designed to accelerateadoption of electric vehicles (“EVs”) and promote innovation, whichis going to have to come from all angles to meet global carbongoals in the next eight years.Sure, it’s simple to say, “everyone just needs to get an electricvehicle,” but it is more complicated than that. Consider that theArgonne National Laboratory is constantly analyzing data to try andfigure out where to put new charging stations to ensure fair accessand that research is still relatively nascent in understandingtemperature-related fluctuations in battery performance. And that’sjust one observation from a 30,000-foot view. At a more granularlevel, new power conversion technologies, like those of Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), are being developed to improve efficiency and curtail EV costs.Hillcrest, a one-time fossil fuels producer, has ditched that modelto pivot into clean energy technologies. The company specializes indeveloping control systems and electric power conversion devicesfor powertrains and charging applications in addition to renewableenergy generation and storage systems.

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Monday's trading session at $0.0823, off by 7.0056%, on 14,350 volume. The average volume for the last 3 months is 14,350 and the stock's 52-week low/high is $0.072/$0.1724.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.